[{"data": {"name": "Do the data really support ordering fragile X testing as a first-tier test without clinical features?", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "Veronique Weinstein", "@type": "Person"}, {"name": "Pranoot Tanpaiboon", "@type": "Person"}, {"name": "Kimberly A Chapman", "@type": "Person"}, {"name": "Nicholas Ah Mew", "@type": "Person"}, {"name": "Sean Hofherr", "@type": "Person"}], "license": "cc-by", "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "http://europepmc.org/articles/pmc5702277?pdf=render", "encodingFormat": "application/pdf"}], "publisher": {"name": "Springer Science and Business Media LLC", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.1038/gim.2017.64", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CC4yBwUL2mVyU-CTXxoVWnW6UuD-CDdLspyfRuE3P-CREbtrLmfN1yd", "propertyID": "ISCC"}], "datePublished": "2017-05-25"}, "schema": "schema.org", "mediatype": "application/ld+json"}]